71 related articles for article (PubMed ID: 10442639)
1. Inhibition of MT-450 rat mammary tumour growth by antibodies recognising subtypes of blood group antigen B.
Sleeman JP; Kim U; LePendu J; Howells N; Coquerelle T; Ponta H; Herrlich P
Oncogene; 1999 Aug; 18(31):4485-94. PubMed ID: 10442639
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen.
Takahashi HK; Metoki R; Hakomori S
Cancer Res; 1988 Aug; 48(15):4361-7. PubMed ID: 3390832
[TBL] [Abstract][Full Text] [Related]
3. Involvement of H type 1 carbohydrate antigen in cell adhesion to vascular endothelial cells of human endometrial cancer.
Sakuma Y; Kubushiro K; Tsukazaki K; Nozawa S
Anticancer Res; 2003; 23(2B):1277-82. PubMed ID: 12820383
[TBL] [Abstract][Full Text] [Related]
4. A tumor-associated organ-specific antigen characteristic of spontaneously metastatic rat mammary carcinomas.
Ghosh SK; Grossberg AL; Kim U; Pressman D
J Natl Cancer Inst; 1979 May; 62(5):1229-33. PubMed ID: 286100
[TBL] [Abstract][Full Text] [Related]
5. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
Galili U
Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
[TBL] [Abstract][Full Text] [Related]
6. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Rabbani SA; Gladu J
Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
[TBL] [Abstract][Full Text] [Related]
7. Case report: diffuse splenic metastasis of occult breast cancer with incompatible blood group antigenic determinants.
Baranyay F
Acta Histochem; 2009; 111(4):343-8. PubMed ID: 19201455
[TBL] [Abstract][Full Text] [Related]
8. Loss of myoepithelial cell characteristics in metastasizing rat mammary tumors relative to their nonmetastasizing counterparts.
Dunnington DJ; Kim U; Hughes CM; Monaghan P; Ormerod EJ; Rudland PS
J Natl Cancer Inst; 1984 Feb; 72(2):455-66. PubMed ID: 6198552
[TBL] [Abstract][Full Text] [Related]
9. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
10. Toremifene resistance in a rat mammary tumour model.
Kellen JA; Georges E; Ling V; Dubsky M
Anticancer Res; 1992; 12(5):1663-5. PubMed ID: 1359832
[TBL] [Abstract][Full Text] [Related]
11. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of blood group A-antigen by a novel anti-A antibody: overcoming ABO-incompatible solid-organ transplantation.
Hasegawa Y; Kato Y; Kaneko MK; Ogasawara S; Shimazu M; Tanabe M; Kawachi S; Obara H; Shinoda M; Kitagawa Y; Narimatsu H; Kitajima M
Transplantation; 2008 Feb; 85(3):378-85. PubMed ID: 18322429
[TBL] [Abstract][Full Text] [Related]
14. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen.
Hooper JD; Zijlstra A; Aimes RT; Liang H; Claassen GF; Tarin D; Testa JE; Quigley JP
Oncogene; 2003 Mar; 22(12):1783-94. PubMed ID: 12660814
[TBL] [Abstract][Full Text] [Related]
15. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.
Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME
Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810
[TBL] [Abstract][Full Text] [Related]
16. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation.
Ganta C; Chiyo D; Ayuzawa R; Rachakatla R; Pyle M; Andrews G; Weiss M; Tamura M; Troyer D
Cancer Res; 2009 Mar; 69(5):1815-20. PubMed ID: 19244122
[TBL] [Abstract][Full Text] [Related]
17. Hormone-responsive growth in vivo of a tissue culture cell line established from the MT-W9A rat mammary tumor.
Sirbasku DA
Cancer Res; 1978 Apr; 38(4):1154-65. PubMed ID: 639042
[No Abstract] [Full Text] [Related]
18. Interleukin-24 induces expression of beta4 integrin but suppresses anchorage-independent growth of rat mammary tumor cells by a mechanism that is independent of beta4.
Xuan W; Li YJ; Liu G; Ben-David Y; Archer MC
Mol Cancer Res; 2009 Mar; 7(3):433-42. PubMed ID: 19258414
[TBL] [Abstract][Full Text] [Related]
19. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis.
Testa JE; Brooks PC; Lin JM; Quigley JP
Cancer Res; 1999 Aug; 59(15):3812-20. PubMed ID: 10447000
[TBL] [Abstract][Full Text] [Related]
20. Metastasis control by injection of blood lymphocytes cultured with neuraminidase-treated MT/W 449A rat mammary carcinoma.
Watkins E; Anderson LL; Baralt OL; Heatley GJ
J Biol Response Mod; 1984; 3(1):60-75. PubMed ID: 6707700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
